Abbott Laboratories

Equities

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 19:04:34 29/04/2024 BST 5-day change 1st Jan Change
107 USD -0.52% Intraday chart for Abbott Laboratories -0.04% -2.77%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee MT
Dexcom's profit beats estimates on strong glucose monitor demand RE
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength RE
Daiwa Securities Trims Abbott Laboratories Price Target to $125 From $126 MT
Barclays Adjusts Abbott Laboratories' Price Target to $140 From $141, Maintains Overweight Rating MT
UBS Raises Abbott Laboratories Price Target to $143 from $136, Buy Rating Kept MT
Correction to Health Care Roundup Article DJ
RBC Lowers Price Target on Abbott Laboratories to $125 From $128, Keeps Outperform Rating MT
Raymond James Adjusts Abbott Laboratories' Price Target to $124 From $127, Keeps Outperform Rating MT
Health Care Down After Abbott Earnings -- Health Care Roundup DJ
Sector Update: Health Care Stocks Retreating Late Afternoon MT
News Highlights : Top Company News of the Day - Wednesday at 3 PM ET DJ
S&P 500, Nasdaq dip as interest rate concerns, earnings weigh RE
Abbott Laboratories Raises Midpoint of 2024 Guidance After First-Quarter Beat MT
Top Stories at Midday: U.S. Bancorp, Abbott, Citizens Financial, First Horizon, Prologis, ASML, Travelers Report Earnings; Tesla Asks Shareholders Vote on Musk's Compensation; Eli Lilly Sleep Apnea Drug Trials Hit Primary Endpoints MT
News Highlights : Top Company News of the Day - Wednesday at 1 PM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET DJ
Wall St slips as dour earnings, chip stocks weigh RE
Sector Update: Health Care Stocks Advance Premarket Wednesday MT
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET DJ
Transcript : Abbott Laboratories, Q1 2024 Earnings Call, Apr 17, 2024
Abbott: target ranges for 2024 tightened upwards CF
Abbott Laboratories' Q1 Adjusted Earnings Down, Revenue Up; 2024 Outlook Narrowed MT
Earnings Flash (ABT) ABBOTT Posts Q1 Revenue $9.96B, vs. Street Est of $9.87B MT
Earnings Flash (ABT) ABBOTT Posts Q1 EPS $0.98, vs. Street Est of $0.95 MT
Chart Abbott Laboratories
More charts
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
107.5 USD
Average target price
126.3 USD
Spread / Average Target
+17.49%
Consensus
  1. Stock Market
  2. Equities
  3. ABT Stock
  4. News Abbott Laboratories
  5. Sector Update: Health Care Stocks Down in Wednesday's Premarket Trading